{"id":15108,"date":"2018-09-26T15:45:31","date_gmt":"2018-09-26T15:45:31","guid":{"rendered":"https:\/\/www.upjs.sk\/pracoviska\/tip\/cib\/focus-of-research\/"},"modified":"2025-06-13T10:35:09","modified_gmt":"2025-06-13T10:35:09","slug":"focus-of-research","status":"publish","type":"page","link":"https:\/\/www.upjs.sk\/pracoviska\/tip\/en\/our-centers\/cib\/focus-of-research\/","title":{"rendered":"Focus of research"},"content":{"rendered":"\n
<\/a>Nanomedicine <\/mark><\/strong><\/p>\n\n\n\n Oncological diseases represent a serious health, psychological and social problem. Due to the aging of the population, changes in lifestyle and environment, their incidence is constantly increasing. Research in the field of nanomedicine at CIB focuses on mitigating the negative consequences of chemotherapy and making anti-cancer treatment more effective through two main approaches:<\/p>\n\n\n\n <\/p>\n\n\n\n Protein Engineering<\/mark><\/strong><\/p>\n\n\n\n The protein engineering research area at CIB is focused on the development and characterization of biomacromolecules – primarily enzymes and binding proteins – with novel or improved properties for applications in biomedicine, diagnostics, biotechnology and synthetic biology. The development of new proteins employs advanced rational design technologies as well as directed evolution methods, including high-throughput screening, ribosome and yeast display.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n Development of staphylokinase as a next-generation thrombolytic agent<\/mark><\/strong><\/p>\n\n\n\n One of the main lines of development is the engineering of staphylokinase, a bacterial protein with potential for thrombolytic therapy. The goal is to create variants of staphylokinase using directed evolution and structural design with:<\/p>\n\n\n\n The staphylokinase constructs under development represent promising biologics for acute thrombotic conditions such as heart attacks and strokes<\/p>\n<\/div>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n Engineering haloalkane dehalogenases for biocatalysis and biosensors<\/mark><\/strong><\/p>\n\n\n\n CIB has a long-standing interest in protein engineering of haloalkane dehalogenases – enzymes capable of catalysing the removal of halogens from organic compounds. They are mainly used in the fields of:<\/p>\n\n\n\n Using directed evolution,<\/strong> structural analysis and modelling of enzyme-substrate interactions, variants with improved specificity, thermostability and substrate tolerance are generated.<\/p>\n\n\n\n <\/p>\n\n\n\n Development of photosensitizers based on the LOV2 domain<\/mark><\/strong><\/p>\n\n\n\n Within optogenetics and photopharmacology,<\/strong> the CIB also develops photosensitizers based on the LOV2 domain<\/strong> (Light-Oxygen-Voltage domain 2), which is sensitive to blue light and allows the control of protein activity by illumination. The aim of the research is to:<\/p>\n\n\n\n These research activities form the basis for the development of smart biomolecules <\/strong>with controlled activity that will find applications in precision medicine, cell biology and synthetic biology.<\/strong><\/p>\n\n\n\n <\/p>\n\n\n\n Ageing and oxidative stress<\/mark><\/strong><\/p>\n\n\n\n This research area integrates the study of the molecular bioenergetics of cellular respiration and the regulation of oxidative stress. The mechanisms of electron and proton transfer in mitochondria, the production of reactive oxygen species, as well as cell death processes associated with mitochondrial dysfunction are investigated.<\/p>\n\n\n\n The results of the research contribute to a deeper understanding of ageing processes and the mechanisms of neurodegenerative and cancer diseases, thus creating prerequisites for the development of new therapeutic strategies.<\/p>\n","protected":false},"excerpt":{"rendered":" Nanomedicine Oncological diseases represent a serious health, psychological and social problem. Due to the aging of the population, changes in lifestyle and environment, their incidence is constantly increasing. Research in the field of nanomedicine at CIB focuses on mitigating the negative consequences of chemotherapy and making anti-cancer treatment more effective through two main approaches: Protein … Continued<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":15101,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"class_list":["post-15108","page","type-page","status-publish","hentry"],"acf":{"acf_link_na_externy_obsah":""},"yoast_head":"\n\n
\n
\n
\n